MedTrace Logo

FDG PET/MR Imaging of Peripheral Pain Generators

NCT06171659 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this research is to determine if a PET/MRI scan using FDG can accurately identify the source of chronic pain. Identifying the source of pain may help doctors treat chronic pain more effectively. Approximately 128 participants will be enrolled and can expect to be on study for up to 12 months.

Conditions

  • Pain
  • Nociceptive Pain

Interventions

DRUG

FDG radiotracer

Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

DEVICE

PET/MRI

positron emission tomography and magnetic resonance imaging

DEVICE

PET/CT imaging

positron emission tomography and computed tomography imaging

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Arthroscopy Association of North America (AANA)

    collaborator UNKNOWN

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Sandip Biswal, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-19
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06171659 on ClinicalTrials.gov